9:35am ET
Investing
Inside Latigo Biotherapeutics’ IPO: A Non-Opioid Pain Bet Goes Public
A California biotech just raised $350 million promising to out-perform opioids without the addiction risk, and its auditors were still warning about survival just months ago. Here is what the science and…